1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Androgenic Alopecia - Pipeline Review, H2 2014

Androgenic Alopecia - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 56 pages

Androgenic Alopecia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Androgenic Alopecia - Pipeline Review, H2 2014’, provides an overview of the Androgenic Alopecia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Androgenic Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Androgenic Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Androgenic Alopecia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Androgenic Alopecia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Androgenic Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Androgenic Alopecia - Pipeline Review, H2 2014
Table of Contents
Introduction 6
Global Markets Direct Report Coverage 6
Androgenic Alopecia Overview 7
Therapeutics Development 8
Pipeline Products for Androgenic Alopecia - Overview 8
Pipeline Products for Androgenic Alopecia - Comparative Analysis 9
Androgenic Alopecia - Therapeutics under Development by Companies 10
Androgenic Alopecia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Androgenic Alopecia - Products under Development by Companies 13
Androgenic Alopecia - Companies Involved in Therapeutics Development 14
Allergan, Inc. 14
Dong-A Socio Group 15
Histogen, Inc. 16
Kasiak Research Pvt. Ltd. 17
Molplex Ltd. 18
Polichem S.A. 19
R-Tech Ueno, Ltd. 20
RepliCel Life Sciences, Inc. 21
RestorGenex Corporation 22
SWITCH Biotech LLC 23
Valeant Pharmaceuticals International, Inc. 24
Androgenic Alopecia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(finasteride + minoxidil) - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
bimatoprost - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
CB-0301 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
finasteride - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Hair Stimulating Complex (HSC) - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
RCH-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Refagro - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
RES-440 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
RK-023 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
SM-04554 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Small Molecule for Androgenic Alopecia - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Small Molecules for Androgenic Alopecia - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Androgenic Alopecia - Recent Pipeline Updates 51
Androgenic Alopecia - Dormant Projects 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables

Number of Products under Development for Androgenic Alopecia, H2 2014 8
Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Androgenic Alopecia - Pipeline by Allergan, Inc., H2 2014 14
Androgenic Alopecia - Pipeline by Dong-A Socio Group, H2 2014 15
Androgenic Alopecia - Pipeline by Histogen, Inc., H2 2014 16
Androgenic Alopecia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 17
Androgenic Alopecia - Pipeline by Molplex Ltd., H2 2014 18
Androgenic Alopecia - Pipeline by Polichem S.A., H2 2014 19
Androgenic Alopecia - Pipeline by R-Tech Ueno, Ltd., H2 2014 20
Androgenic Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2014 21
Androgenic Alopecia - Pipeline by RestorGenex Corporation, H2 2014 22
Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2014 23
Androgenic Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Assessment by Combination Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Androgenic Alopecia Therapeutics - Recent Pipeline Updates, H2 2014 51
Androgenic Alopecia - Dormant Projects, H2 2014 54

List of Figures

Number of Products under Development for Androgenic Alopecia, H2 2014 8
Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Top 10 Targets, H2 2014 27
Number of Products by Stage and Top 10 Targets, H2 2014 28
Number of Products by Top 10 Mechanism of Actions, H2 2014 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Top 10 Routes of Administration, H2 2014 31
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 32
Number of Products by Top 10 Molecule Types, H2 2014 33
Number of Products by Stage and Top 10 Molecule Types, H2 2014 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.